Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 1.11T with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue Recognition for Large-Scale Manufacturing Agreement This disclosure represents a major…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract / 2025-12-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Yoon OO and 1,230 minority shareholders (1.71% stake) have filed a lawsuit against Celltrion seeking court permission to convene an Extraordinary General Meeting of Shareholders regarding treasury share cancellation, articles amendment, and director dismissal. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Filing / Application of Lawsuit (Management Control Dispute) / 2025-12-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the setting of December 31, 2025, as the record date and established a shareholder register closure period to identify shareholders entitled to vote at the 15th Annual General Meeting of Shareholders. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key…

Read More “[Disclosure] Samsung Biologics (207940) – Setting of Record Date or Period for Suspension of Entry of Change in Shareholders / 2025-12-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure extending the disclosure postponement period from December 31, 2025, to December 31, 2031, at the customer’s request regarding the contract manufacturing agreement with UCB originally disclosed on May 17, 2019. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-12-12” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has set December 31, 2025, as the record date to confirm entitled shareholders for the 35th fiscal period year-end dividend. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Dividend Amounts and Annual General Meeting Schedule Following Record…

Read More “[Disclosure] Celltrion (068270) – Decision on Closure of Shareholders’ Register (Record Date) for Cash/Goods Dividend / 2025-12-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided on a year-end cash dividend of KRW 750 per common share (totaling approx. KRW 164.0B, dividend yield of 0.4%) for FY2025, funded by capital reserve reduction for tax-exempt status. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Decision on Cash and Goods Dividend / 2025-12-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion’s US subsidiary (Celltrion USA, Inc.) has finalized the expected acquisition date of December 31, 2025, for its 100% equity purchase of Imclone Systems LLC to establish a US API manufacturing base. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Decision on Acquisition of Shares and Equity Securities of Other Corporation (Correction) / 2025-12-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion’s US subsidiary, Celltrion USA, Inc., has decided on a rights offering worth USD 532.1M (approx. KRW 782.4B) to fund the acquisition of a US API manufacturing facility and secure working capital. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Decision on Capital Increase by Rights Offering (Major Management Matters of Subsidiary) / 2025-12-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to participate in a rights issue by its US subsidiary, Celltrion USA, Inc., investing approximately KRW 782.4B (4.45% of total equity) to fund the acquisition of a US API manufacturing facility and provide working capital. 📊 [Key Disclosure Details & Financial Summary] 📝…

Read More “[Disclosure] Celltrion (068270) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-12-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN held an Extraordinary General Meeting of Shareholders (EGM) and approved all proposed agenda items, including the conditional delisting from KOSDAQ and transfer listing to KOSPI. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of KOSPI Transfer Listing…

Read More “[Disclosure] ALTEOGEN (196170) – Results of Extraordinary General Meeting of Shareholders / 2025-12-08” »